CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX EBITDA Margin

EBITDA as a percentage of revenue.

CytomX Therapeutics, Inc.NASDAQ: CTMX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -174.9%

EBITDA Margin was -174.9% in Q1 FY2026, down 221.9 pp from a year earlier. On a trailing-twelve-month basis it was -162.2%, down 191.7 pp year over year. Over 3 fiscal years it widened by 161.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -239.7% for the fiscal year ending Dec 2026, down from -20.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-174.9%+3738.6 pp QoQ
Last fiscal yearDec 2025
-20.7%-45.2 pp YoY
LTMMar 2026
-162.2%-191.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-221.9 pp-137.3 pp+84.6 pp
1 year-45.2 pp-219.0 pp-173.8 pp
3 years+161.5 pp-165.8 pp-327.4 pp
5 years+26.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-20.7%
Year-over-year change
-45.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 EBITDA Margin of -162.2% is the 7th highest of the 10 companies compared; the peer median is -106.5%.
  • Its year-over-year change of -191.7 pp is the 7th highest of 8, against a peer median of +22.1 pp.
  • Over three fiscal years its change of +161.5 pp compares with a peer median of +1.6 pp.
CTMX Competitors Peer median
EBITDA Margin for CTMX and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
ZYMEZymeworks Inc.LTM Sep 202621.5% +61.6 pp-99.3 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
ADCTADC Therapeutics S.A.LTM Mar 2026-105.1% +22.1 pp-58.4 pp
STROSutro Biopharma, Inc.LTM Mar 2026-106.5% +169.1 pp+12.9 pp
XNCRXencor, Inc.LTM Jun 2026-117.7% -51.9 pp-9.6 pp
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-162.2% -191.7 pp+161.5 pp
PYXSPyxis Oncology, Inc.LTM Mar 2026-547.9% ——
ADAGAdagene Inc.LTM Jun 2024-4420.7% —+613.1 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-272652.7% -264146.9 pp-12607.1 pp
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding CTMX) -106.5%+22.1 pp+1.6 pp

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.31M53.16M101.21M138.1M76.2M
Cost of Revenue00000
Gross Profit37.31M53.16M101.21M138.1M76.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development114.19M111.65M77.68M83.38M68.73M
Selling, General & Admin39.16M42.85M30.02M29.73M29.84M
Operating Expenses153.35M154.5M107.7M113.11M98.57M
Depreciation & Amortization2.71M2.44M2.18M1.77M1.38M
EBITDA(113.16M)(96.87M)5.5M33.86M(15.75M)
EBITDA Margin-303.3%-182.2%5.4%24.5%-20.7%
Operating Income(116.04M)(101.34M)(6.48M)25M(22.36M)
Operating Margin-311.0%-190.6%-6.4%18.1%-29.3%
Interest Income255K1.68M9.84M7.14M5.21M
Interest Expense00000
Other Income / Expenses172K2.02M9.81M7.1M5.23M
Income Before Tax(115.87M)(99.32M)3.32M32.09M(17.13M)
Pre-Tax Margin-310.5%-186.8%3.3%23.2%-22.5%
Income Tax Expense003.89M224K238K
Net Income(115.87M)(99.32M)(569K)31.87M(17.37M)
Net Margin-310.5%-186.8%-0.6%23.1%-22.8%
EPS (Basic)(1.26)(1.48)(0.01)0.38(0.15)
EPS (Diluted)(1.26)(1.48)(0.01)0.38(0.15)
Weighted Avg Shares64.15M65.74M73.81M84.44M137.94M
Weighted Avg Shares (Diluted)64.15M65.74M73.81M84.75M137.94M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.